Amgen Inc. (ETR:AMG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 131.74B |
| Revenue (ttm) | 31.57B |
| Net Income (ttm) | 5.49B |
| Shares Out | n/a |
| EPS (ttm) | 10.12 |
| PE Ratio | 24.00 |
| Forward PE | 13.40 |
| Dividend | 8.59 (3.52%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 180 |
| Average Volume | 414 |
| Open | 247.15 |
| Previous Close | 243.70 |
| Day's Range | 245.15 - 247.70 |
| 52-Week Range | 230.75 - 318.05 |
| Beta | 0.50 |
| RSI | 45.93 |
| Earnings Date | Apr 25, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m.
3 Stocks That Will Profit From Trump's Drug Price Cut
On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to th...
Regeneron wins over $400M jury award as Amgen found liable in antitrust case
Amgen owes $406 million for monopolizing cholesterol drug market, US jury says
A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-re...
Amgen owes $406 million for monopolizing cholesterol drug market, US jury says
(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cho...
Stock Of The Day: Amgen Slips With Healthcare Sector, But Signals Point To A Reversal
The stock of Amgen Inc. (NASDAQ: AMGN) is trading higher on Thursday. But along with the rest of the healthcare sector, it is still in a steep downtrend. The news regarding potential fraud at UnitedH...
Stock Of The Day: Amgen Slips With Healthcare Sector, But Signals Point To A Reversal
The stock of Amgen Inc. AMGN is trading higher on Thursday. But along with the rest of the healthcare sector, it is still in a steep downtrend.
Dow Jones Today: Indices Rise on Cisco Surge, But DOJ Probe Hits UnitedHealth
Dow rises as Cisco and Amgen rally, but UnitedHealth drags after DOJ probe. Inflation cools, retail sales steady. Outlook hinges on Fed and tariffs.
Amgen Inc. (AMGN) BofA Securities 2025 Healthcare Conference (Transcript)
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.
European pharma stocks follow Asia peers down as Trump moves to cut prices
European drugmakers stocks fell in early trading on Monday after U.S. President Donald Trump said he would sign an executive order on reducing prescription drug and pharmaceutical prices.
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m.
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI
Claremont, CA, May 08, 2025 (GLOBE NEWSWIRE) -- During the Keck Graduate Institute commencement ceremony on May 17, 2025, Robert A. Bradway will receive an honorary Doctor of Philosophy in Applied Lif...
Amgen’s Tepezza becomes first U.K.-medicine approved for adults with thyroid eye disease
What the Options Market Tells Us About Amgen
Investors with a lot of money to spend have taken a bearish stance on Amgen (NASDAQ: AMGN). And retail traders should know. We noticed this today when the trades showed up on publicly available optio...
Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom
CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as ...
VP Of Amgen Sold $279K In Stock
Matthew C Busch , VP at Amgen (NASDAQ: AMGN), executed a substantial insider sell on May 7, according to an SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission...
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
BeiGene Ltd. (NASDAQ: ONC) stock is trading lower after the company reported mixed first-quarter 2025 financial results on Wednesday . The Chinese biotech reported adjusted earnings per ADS of $1.22,...
Amgen: Waiting Patiently For A Real Catalyst
Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1
Dogs Of The Dow Chase May's 'Safer' Buy
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding the single share price, supported by adequate free cash flow. Analyst projections suggest top Dow Dogs cou...
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
Amgen Inc. (NASDAQ: AMGN) reported first-quarter sales of $8.15 billion on Thursday, u p 9% year over year and beating the consensus of $8.06 billion . Product sales grew 11%, primarily driven by 14%...